Genetic testing for hereditary breast cancer: The decision to decline.

1552 Background: Genetic testing is an important component of comprehensive cancer care. Testing for hereditary breast and ovarian cancer syndrome is well established, as commercial analysis of the BRCA1/2 genes has been available since 1996. The National Comprehensive Cancer Network (NCCN) guidelines identify those individuals appropriate for BRCA1/2 analysis, and define management recommendations for mutation carriers. Despite recommendations, not all who meet NCCN criteria undergo genetic testing. We assess the frequency that individuals meeting NCCN criteria decline BRCA1/2 analysis, as well as factors that affect the decision making process. Methods: A retrospective chart review was performed from September 2013 through August 2014 of individuals who had genetic counseling at the Levine Cancer Institute (LCI). Results: 1083 individuals identified through the retrospective chart review met NCCN criteria for BRCA1/2 analysis. 268 (24.5%) of the 1083 individuals did not pursue genetic testing. Of those ...